<DOC>
	<DOCNO>NCT00001880</DOCNO>
	<brief_summary>The goal research study identify type cancer ( malignant neoplasm ) may treatable stem cell transplantation ( allogenic peripheral blood stem cell transplantation . Patients variety different type cancerous tumor spread ( metastasize ) whose condition improve stand therapy , eligible participate . Those patient select participate study undergo procedure know `` mini-transplant '' . The mini-transplant transplantation stem-cells collect sibling ( brother sister ) patient . Unlike traditional bone marrow transplant , mini-transplant require intense chemotherapy radiation therapy . Because , patient experience few less severe side effect . This study open patient diagnose variety metastatic solid tumor include esophageal , gastric ( stomach ) , colon , rectal , liver tumor ( hepatoma ) , cancer biliary system ( cholangiocarcinoma ) , cancer pancreas , lung , breast , prostate , bone ( sarcoma ) , adrenal basal cell , bladder , adenocarcinomas unk primary origin ... .</brief_summary>
	<brief_title>Stem Cell Transplantation Metastatic Solid Tumors</brief_title>
	<detailed_description>The main objective study identify metastatic neoplasm , may susceptible GVT effect . We treat patient progressive metastatic solid tumor refractory standard therapy non-myeloablative allogeneic PBSC transplant family donor . A GVT effect immunocompetent donor immune cell could extend life expectancy possibly cure patient . Eligible patient treat allogeneic peripheral blood stem cell transplant HLA identical single HLA antigen-mismatched family donor , use intensive immunosuppressive regimen without myeloablation ( `` mini-transplant '' ) attempt decrease transplant related toxicity preserve anti-malignancy and/or anti-host marrow effect graft . The low intensity non-myeloablative conditioning regimen provide adequate immunosuppression allow stem cell lymphocyte engraftment . A T-cell replete , donor-derived , granulocyte colony stimulate factor ( G-CSF ) -mobilized peripheral blood stem cell ( PBSC ) use establish hematopoietic lymphoid reconstitution . We infuse lymphocytes patient &lt; 100 % donor T-cell chimerism evidence tumor progression attempt prevent graft rejection enhance graft-versus-malignancy effect , respectively . This trial open several different type metastatic , treatment-refractory , solid neoplasm , breast , cholangiocarcinoma , small intestine/colon/rectal adenocarcinoma , esophageal/gastric , hepatocellular , pancreatic , prostate , bony/soft tissue sarcoma . The trial design permit 10 patient specific tumor type enrol screen anti-tumor effect . A single complete response specific tumor type indication exclude patient diagnosis study . Subsequently , new protocol focus define GVT effect disease category institute .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Cholangiocarcinoma</mesh_term>
	<criteria>INCLUSION CRITERIA : PATIENTS : Patients metastatic solid tumor ( breast , cholangiocarcinoma , small intestine/colon/rectal , adenocarcinoma , esophageal/gastric , hepatocellular , pancreatic , prostate , bony/soft tissue sarcoma , histologically confirm , progressive incurable . Due low accrual , effective 12/19/2006 , patient adrenal , basal cell , transitional cell carcinoma bladder uroepithelium , ovarian , small cell lung cancer , non small cell lung cancer , adenocarcinomas unknown primary origin longer eligible trial . Age great equal 10 less equal 80 . No known standard therapy patient 's disease potentially curative definitely capable extend life expectancy . Metastatic disease , bidimensionally evaluable radiographically . No prior treatment neoplasm within 30 day . &lt; TAB &gt; &lt; TAB &gt; Ability comprehend investigational nature study provide inform consent . Availability HLA identical single HLAlocus mismatch family donor . &lt; TAB &gt; &lt; TAB &gt; Willingness availability return NIH schedule followup . DONOR : HLA identical single HLAlocus mismatch family donor . Age great equal 10 80 year old . Ability comprehend investigational nature study provide inform consent . EXCLUSION CRITERIA : PATIENT : Pregnant lactating . Age le 10 great 80 year . ECOG performance status 3 . Psychiatric disorder mental deficiency severe make compliance BMT treatment unlikely , make informed consent impossible . Major anticipated illness organ failure incompatible survival PBSC transplant . DLCO : le 40 % predict . Left ventricular ejection fraction : le 30 % . Serum creatinine great 2.5mg/dl creatinine clearance le 50 cc/min 24 hr urine collection . Serum bilirubin great 4 mg/dl Transaminases great 5 time upper limit normal . Oral intake less 1,200 calories/day . Recent weight loss great equal 10 % actual body weight . Life expectancy le 3 month Therapy malignancy within 4 week begin protocol . CNS metastatic disease associate intracranial bleeding , uncontrolled seizure disorder significant intracranial mass effect . &lt; TAB &gt; &lt; TAB &gt; Other malignant disease liable relapse progress within 5 year . &lt; TAB &gt; &lt; TAB &gt; Uncontrolled infection . DONOR : Pregnant lactating . Donor unfit receive GCSF undergo apheresis . ( Uncontrolled hypertension , history congestive heart failure unstable angina , thrombocytopenia ) . Age le 10 great 80 year . HIV positive . Donors positive HBV , HCV HTLVI may use discretion investigator follow counsel approval recipient .</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 30, 2016</verification_date>
	<keyword>Graft-Versus-Tumor</keyword>
	<keyword>Peripheral Blood Stem Cells</keyword>
	<keyword>Non-Myeloablative Bone Marrow Transplantation</keyword>
	<keyword>Metastatic Solid Tumors</keyword>
	<keyword>Engraftment</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Fludarabine</keyword>
	<keyword>Donor Apheresis</keyword>
	<keyword>Graft-Versus-Host Disease</keyword>
	<keyword>Cancer</keyword>
	<keyword>Tumor</keyword>
</DOC>